Puran Chen, Peter Bergman, Ola Blennow, Lotta Hansson, Stephan Mielke, Piotr Nowak, Gunnar Söderdahl, Anders Österborg, C I Edvard Smith, Jan Vesterbacka, David Wullimann, Angelica Cuapio, Mira Akber, Gordana Bogdanovic, Sandra Muschiol, Mikael Åberg, Karin Loré, Margaret Sällberg Chen, Marcus Buggert, Per Ljungman, Soo Aleman, Hans-Gustaf Ljunggren
BACKGROUND: Immunocompromised patients have varying responses to SARS-CoV-2 mRNA vaccination. However, there is limited information available from prospective clinical trial cohorts with respect to long-term immunogenicity-related responses in these patient groups following three or four vaccine doses, and in applicable cases infection. METHODS: In a real-world setting, we assessed the long-term immunogenicity-related responses in patients with primary and secondary immunodeficiencies from the prospective open-label clinical trial COVAXID...
August 2023: EBioMedicine